circulating tumor DNA(English)

• has emerged as a potential new biomarker with diagnostic, predictive, and prognostic applications for various solid tumor types. Before beginning large prospective clinical trials to prove the added value of utilizing ctDNA in clinical practice, it is essential to investigate the effects of various preanalytical conditions on the quality of cell-free DNA in general and of ctDNA in particular in order to optimize and standardize these conditions
• CFDNA, CDx
• Diagnostics, Biomarker, Biopsy
• https://doi.org…1878-0261.12037
• https://doi.org…cer.2022.03.013